142 related articles for article (PubMed ID: 30943159)
1. [Experiences and reflections in the paediatric context - From label to delivery of an innovative treatment: what a journey! (1)].
Cancès C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():32-34. PubMed ID: 30943159
[No Abstract] [Full Text] [Related]
2. [An institutional point of view - From label to delivery of an innovative treatment: what a journey! (4)].
Belcastro J
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():39-41. PubMed ID: 30943162
[No Abstract] [Full Text] [Related]
3. [Anticipating changes and risks in adults - From label to delivery of an innovative treatment: what a journey! (2)].
Antoine JC
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():35-36. PubMed ID: 30943160
[No Abstract] [Full Text] [Related]
4. After Avandia, some seek split in drug approval and monitoring.
Dolgin E
Nat Med; 2010 Aug; 16(8):831. PubMed ID: 20689527
[No Abstract] [Full Text] [Related]
5. Introduction and overview: why another polemic on ethics?
Freeman JM
Pediatr Ann; 1992 May; 21(5):279-81. PubMed ID: 1625942
[No Abstract] [Full Text] [Related]
6. [Practical approach of lymphomas: major role of general practitioner who has to face all these emerging drugs].
Bron D; Dewind R; Cantinieaux B; Woff E; Roelandts M; Moerman C; Lemort M; Heimann P; De Wilde V; Meuleman N; Maerevoet M
Rev Med Brux; 2015 Sep; 36(4):237-47. PubMed ID: 26591307
[TBL] [Abstract][Full Text] [Related]
7. New modalities of prescription of ATUns: Evolutions and revolution.
Vignot S; Plaine G; Chapel E
Rev Neurol (Paris); 2020 May; 176(4):290-292. PubMed ID: 31611006
[No Abstract] [Full Text] [Related]
8. Canadian and US drug approval times and safety considerations.
Rawson NS; Kaitin KI
Ann Pharmacother; 2003 Oct; 37(10):1403-8. PubMed ID: 14519031
[TBL] [Abstract][Full Text] [Related]
9. [The organization of pharmacovigilance in France, in Europe and worldwide - From label to delivery of an innovative treatment: what a journey! (3)].
Lebrun-Vignes B
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():37-39. PubMed ID: 30943161
[No Abstract] [Full Text] [Related]
10. [Legal issues in the off-label use of drug medication in in pediatrics].
Poetsch J
J Dtsch Dermatol Ges; 2006 May; 4(5):421-6. PubMed ID: 16686611
[No Abstract] [Full Text] [Related]
11. Postmarketing surveillance of new antiepileptic drugs: the tribulations of trials.
French JA
Epilepsia; 2002 Sep; 43(9):951-5. PubMed ID: 12199719
[No Abstract] [Full Text] [Related]
12. Medical physicists should not encourage or participate in off-label, non-FDA-approved uses of intravascular brachytherapy devices. For the proposition.
Jani SK
Med Phys; 2002 Sep; 29(9):2128-9. PubMed ID: 12349933
[No Abstract] [Full Text] [Related]
13. On the humane side of medicine.
Khuri FR
Cancer; 2018 Oct; 124(20):3969-3970. PubMed ID: 30341982
[No Abstract] [Full Text] [Related]
14. Approval times and the safety of new pharmaceuticals.
Rudholm N
Eur J Health Econ; 2004 Dec; 5(4):345-50. PubMed ID: 15452739
[TBL] [Abstract][Full Text] [Related]
15. A primer of drug safety surveillance: an industry perspective. Part I: Information flow, new drug development, and federal regulations.
Allan MC
J Pharm Technol; 1992; 8(4):162-7. PubMed ID: 10121011
[TBL] [Abstract][Full Text] [Related]
16. [Nusinersen in SMA children: evolution or revolution? - Clinical use of innovative, repurposed or off-label therapies: a real life experience (2)].
Richelme C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():22-25. PubMed ID: 30943156
[No Abstract] [Full Text] [Related]
17. [Following together the road to accessing innovative therapies: a few landmarks].
Cottet C
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():57-59. PubMed ID: 30943167
[No Abstract] [Full Text] [Related]
18. [Congenital myasthenic syndromes: repurposing does not simplify access de facto - Clinical use of innovative, repurposed or off-label therapies: a real life experience (4)].
Eymard B
Med Sci (Paris); 2019 Mar; 35 Hors série n° 1():28-31. PubMed ID: 30943158
[No Abstract] [Full Text] [Related]
19. The FDA drug approval process: focus on pediatric labeling.
Brummel GL
Neonatal Netw; 2001 Apr; 20(3):49-51. PubMed ID: 12144214
[No Abstract] [Full Text] [Related]
20. FDA's monitoring of postmarketing studies probed.
Young D
Am J Health Syst Pharm; 2006 Aug; 63(16):1485-6. PubMed ID: 16896075
[No Abstract] [Full Text] [Related]
[Next] [New Search]
